<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Abiraterone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB05812</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. <span class="caps">FDA</span> approved on April 28, 2011.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB05812/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB05812/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05812.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05812.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05812.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05812.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05812.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB05812">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Zytiga </td><td>Janssen Biotech</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>154229-19-3</td></tr><tr><th>Weight</th><td>Average: 349.509<br>Monoisotopic: 349.240564619</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>31</sub>NO</td></tr><tr><th>InChI Key</th><td>GZOSMCIZMLWJML-VJLLXTKPSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0&#178;,&#8311;.0&#185;&#185;,&#185;&#8309;]heptadeca-7,13-dien-5-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Androgens and Derivatives</td></tr><tr><th>Direct parent</th><td>Androgens and Derivatives</td></tr><tr><th>Alternative parents</th><td>Hydroxysteroids; Cyclohexanols; Pyridines and Derivatives; Cyclic Alcohols and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>cyclohexanol; pyridine; cyclic alcohol; secondary alcohol; polyamine; organonitrogen compound; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the androgens and derivatives. These are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. </td></tr><tr><th>Pharmacodynamics</th><td>Abiraterone is associated with decreases in PSA levels, tumor shrinkage (as evaluated by RECIST criteria), radiographic regression of bone metastases and improvement in pain. Levels of adrenocorticotropic hormones increased up to 6-fold but this can be suppressed by dexamethasone. </td></tr><tr><th>Mechanism of action</th><td>Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism. CYP17A1 is an enzyme that catalyzes the biosynthesis of androgen and is highly expressed in testicular, adrenal, and prostatic tumor tissue. More specifically, abiraterone inhibits the conversion of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 to decrease serum levels of testosterone and other androgens. </td></tr><tr><th>Absorption</th><td>Abiraterone itself is poorly absorbed and is susceptible to hydrolysis by esterases. The salt form, abiraterone acetate, is a prodrug which has a much higher oral bioavailability and is also esterase resistant. Peak drug concentrations of abiraterone were reached in 1.5 - 4 hours. Abiraterone acetate was rapidly and completely deacetylated into abiraterone-the parent salt form was not detectable in early pharmacokinetic studies. Food and high fat meals increases absorption 4.4-fold. </td></tr><tr><th>Volume of distribution</th><td><p>Vdss= 19,669 &#177; 13,358 L</p></td></tr><tr><th>Protein binding</th><td>&gt;99% protein bound to alpha-1-acid glycoprotein and albumin. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Abiraterone acetate is hydrolyzed into active metabolite abiraterone via esterases. CYP3A4 and SULT2A1 further metabolizes abiraterone into two inactive metabolites called abiraterone sulfate and N-oxide abiraterone sulfate. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Abiraterone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00788">abiraterone sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/809">Details</a></td></tr><tr><td>Abiraterone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00951">N-oxide abiraterone sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/972">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Excreted via feces (~88%) and urine (~5%) </td></tr><tr><th>Half life</th><td>Terminal elimination half-life = 5-14 hours </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Toxicity is related to the blockade of 17&#945;-hydroxylase activity. Blockade results in the accumulation of upstream mineralocorticoids like 11-deoxycorticosterone leading to secondary hyperaldosteronism. Signs of hydroaldosteronism include fluid retention and hypokalemia. Mineralocorticoid receptor antagonists may be used to treat signs and symptoms. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.98</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7245</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6583</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8831</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7453</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.854</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6478</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5124</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8046</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8693</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5349</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7176</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5363</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8499
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9616
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9565
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4407 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8318
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7059
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>250 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB06616">Bosutinib</a></td><td>Abiraterone increases levels by P-glycoprotein (MDR1) efflux transporter. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01201">Rifapentine</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food and high fat meals increases the drug exposure 4.4-fold. It is suggested that abiraterone is taken on an empty stomach. </li></ul></td></tr></tbody></table>